Core Insights - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on biotech, defense, aerospace, and national-security technologies [1] - The company appointed Paolo Salvato to the Board of Directors of ATC, marking its entry into defense technology manufacturing [1] - Genenta is evaluating acquisition opportunities in regulated national-security sectors to build a strategic industrial consolidator [3] Company Developments - Paolo Salvato has over two decades of experience in defense industrial operations, previously serving as CEO of Fiocchi Munizioni and Thales Italia [2] - The company aims to acquire profitable, majority-controlled, privately-held industrial businesses, leveraging its Nasdaq listing for financial flexibility [4][6] - Genenta's biotech program has reached clinical maturity, with a focus on strategic partnerships to advance development and minimize risk [6] Clinical and Scientific Progress - Nature Medicine has accepted a manuscript detailing clinical findings from Genenta's Glioblastoma Multiforme trial, expected to be published soon [5] - The publication is seen as a validation of the company's scientific and clinical efforts [5] Strategic Vision - The transformation reflects a response to evolving market dynamics, with an emphasis on the intersection of advanced biotechnology and defense technologies [6] - The company is focused on acquiring businesses with positive EBITDA and integrating them into a transparent, publicly listed platform for long-term value creation [6]